Autonomic involvement in hereditary transthyretin amyloidosis (hATTR amyloidosis)

No abstract is available for this paper.

• Publication year

  2019

• Venue

  Clinical Autonomic Research

• Publication date

  2019-04-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1007/s10286-018-0514-2PMID 29511897
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Health utilities in acute myeloid leukemia: A comprehensive literature review

  2017cited by this paper
• Cutaneous nerve biomarkers in transthyretin familial amyloid polyneuropathy

  2017cited by this paper
• Trial design and rationale for APOLLO, a Phase 3, placebo-controlled study of patisiran in patients with hereditary ATTR amyloidosis with polyneuropathy

  2017cited by this paper
• Gastrointestinal Amyloidosis: Review of the Literature

  2017cited by this paper
• Assessing mNIS+7Ionis and international neurologists' proficiency in a familial amyloidotic polyneuropathy trial

  2017influential reference
• Clinical measures in transthyretin familial amyloid polyneuropathy

  2017cited by this paper
• Transthyretin amyloid neuropathy has earlier neural involvement but better prognosis than primary amyloid counterpart: an answer to the paradox?

  2016cited by this paper
• “Red‐flag” symptom clusters in transthyretin familial amyloid polyneuropathy

  2016cited by this paper
• Monitoring effectiveness and safety of Tafamidis in transthyretin amyloidosis in Italy: a longitudinal multicenter study in a non-endemic area

  2016cited by this paper
• TTR kinetic stabilizers and TTR gene silencing: a new era in therapy for familial amyloidotic polyneuropathies

  2016cited by this paper
• Parenteral nutrition improves nutritional status, autonomic symptoms and quality of life in transthyretin amyloid polyneuropathy.

  2016cited by this paper
• Safety and efficacy of long-term diflunisal administration in hereditary transthyretin (ATTR) amyloidosis

  2015cited by this paper
• Alternative therapies to address the unmet medical needs of patients with phenylketonuria

  2015cited by this paper
• Evolving landscape in the management of transthyretin amyloidosis

  2015cited by this paper
• Sudomotor innervation in transthyretin amyloid neuropathy: Pathology and functional correlates

  2015cited by this paper
• A Review of Tafamidis for the Treatment of Transthyretin-Related Amyloidosis

  2015cited by this paper
• Rapid progression of familial amyloidotic polyneuropathy

  2015cited by this paper
• Validation of the composite autonomic symptom scale 31 (COMPASS‐31) in patients with and without small fiber polyneuropathy

  2015cited by this paper
• Efficacy of diflunisal on autonomic dysfunction of late-onset familial amyloid polyneuropathy (TTR Val30Met) in a Japanese endemic area.

  2014cited by this paper
• Nomenclature 2014: Amyloid fibril proteins and clinical classification of the amyloidosis

  2014cited by this paper
• Norfolk QOL‐DN: validation of a patient reported outcome measure in transthyretin familial amyloid polyneuropathy

  2014cited by this paper
• Autonomic Neuropathy in Diabetes Mellitus

  2014cited by this paper
• Guideline of transthyretin-related hereditary amyloidosis for clinicians

  2013cited by this paper
• Amyloidosis: a clinical overview.

  2013cited by this paper
• Amyloid neuropathies.

  2012cited by this paper
• Familial amyloidotic polyneuropathy: current and emerging treatment options for transthyretin-mediated amyloidosis

  2012cited by this paper
• Amyloid and Related Disorders

  2012cited by this paper
• Stem cell transplantation in patients with autonomic neuropathy due to primary (AL) amyloidosis

  2010cited by this paper
• Near-infrared spectrophotoscopy of finger venules in assessment of autonomic dysfunction

  2004cited by this paper
• Myocardial Muscarinic Receptor Upregulation and Normal Response to Isoproterenol in Denervated Hearts by Familial Amyloid Polyneuropathy

  2001cited by this paper
• Endothelium‐dependent vasodilatation in patients with familial amyloidotic polyneuropathy

  2000cited by this paper
• Autonomic dysfunction in familial amyloidotic polyneuropathy (FAP).

  1998influential reference
• Diabetic polyneuropathy in controlled clinical trials: Consensus report of the peripheral nerve society

  1995cited by this paper
• Radiolabelled meta-iodobenzylguanidine in assessment of autonomic dysfunction.

  1994cited by this paper
• Familial amyloidosis: a study of 52 North American-born patients examined during a 30-year period.

  1992cited by this paper
• Autonomic neuropathy in familial amyloidotic polyneuropathy

  1989cited by this paper
• Scalloped pupils in familial amyloid polyneuropathy.

  1986cited by this paper

• Autonomic dysfunction in patients with wild-type transthyretin amyloidosis

  2026cites this paper
• Sudoscan in ATTRv Amyloidosis: A Potential Marker of Disease Progression?

  2025cites this paper
• Central nervous system involvement in cardiac amyloidosis: Redefining the heart‐brain axis

  2025cites this paper
• Transthyretin variants impact blood-nerve barrier and neuroinflammation in amyloidotic neuropathy.

  2025cites this paper
• Amyloidosis for the Gastroenterologist: A Comprehensive Systematic Review of Diagnosis and Management of Gastrointestinal Manifestations

  2025cites this paper
• Long-term treatment of hereditary transthyretin amyloidosis with patisiran: multicentre, real-world experience in Italy

  2024cites this paper
• Neuromuscular manifestations of wild type transthyretin amyloidosis: a review and single center’s experience

  2024cites this paper
• Evaluation of autonomic dysfunction in hereditary transthyretin amyloidosis.

  2024cites this paper
• Diagnosis and treatment of hereditary transthyretin amyloidosis with polyneuropathy in the United States: Recommendations from a panel of experts

  2024cites this paper
• Phenotype variability and therapeutic response to Patisiran in patients with hereditary transthyretin amyloidosis: a Belgian real-world experience

  2024cites this paper
• Early autonomic biomarkers in ATTRv carriers

  2023cites this paper
• What a neurologist must know of hereditary ATTRv amyloidosis

  2023influential citation
• Cardiovascular reflex tests detect autonomic dysfunction in symptomatic and pre-symptomatic subjects with hereditary transthyretin amyloidosis

  2023cites this paper
• Identification and management of gastrointestinal manifestations of hereditary transthyretin amyloidosis: Recommendations from an Italian group of experts.

  2023cites this paper
• A narrative review and expert recommendations on the assessment of the clinical manifestations, follow-up, and management of post-OLT patients with ATTRv amyloidosis

  2023cites this paper
• Implications of Extra-cardiac Disease in Patient Selection for Heart Transplantation: Considerations in Cardiac Amyloidosis

  2023cites this paper
• Brazilian consensus for diagnosis, management and treatment of hereditary transthyretin amyloidosis with peripheral neuropathy: second edition

  2022cites this paper
• Characteristics of patients with autonomic dysfunction in the Transthyretin Amyloidosis Outcomes Survey (THAOS)

  2022cites this paper
• Impact of baseline polyneuropathy severity on patisiran treatment outcomes in the APOLLO trial

  2022cites this paper
• Follow-up regimens for carriers of hereditary transthyretin variants.

  2022cites this paper
• Noncardiac Manifestations of Hereditary Amyloidosis.

  2022cites this paper
• Diagnostic and Prognostic Values of Cardiopulmonary Exercise Testing in Cardiac Amyloidosis

  2022cites this paper
• Expert opinion on monitoring symptomatic hereditary transthyretin-mediated amyloidosis and assessment of disease progression

  2021cites this paper
• Pupillometry: An objective test to assess endocular hereditary transthyretin amyloidosis

  2021cites this paper
• Screening for ATTR amyloidosis in the clinic: overlapping disorders, misdiagnosis, and multiorgan awareness

  2021cites this paper
• A simple core dataset and disease severity score for hereditary transthyretin (ATTRv) amyloidosis

  2021influential citation
• Validation of the Korean version of the Boston Autonomic Symptom Questionnaire

  2021cites this paper
• Interpreting signals from the peripheral nerve in amyloidosis: a call for action

  2021cites this paper
• Hereditary transthyretin-mediated amyloidosis with polyneuropathy: baseline anthropometric, demographic and disease characteristics of patients from a reference center

  2021cites this paper
• Safety and Tolerability of Neurohormonal Antagonism in Cardiac Amyloidosis.

  2020cites this paper
• Quality of life outcomes in APOLLO, the phase 3 trial of the RNAi therapeutic patisiran in patients with hereditary transthyretin-mediated amyloidosis

  2020cites this paper
• Val50Met hereditary transthyretin amyloidosis: not just a medical problem, but a psychosocial burden

  2020cites this paper
• Neuropathy Associated with Hereditary Transthyretin Amyloidosis—Diagnosis and Management

  2020cites this paper
• Hereditary transthyretin amyloidosis overview

  2020cites this paper
• Indirect treatment comparison of the efficacy of patisiran and inotersen for hereditary transthyretin-mediated amyloidosis with polyneuropathy

  2020cites this paper
• Strategies to improve the quality of life in patients with hereditary transthyretin amyloidosis (hATTR) and autonomic neuropathy

  2019cites this paper
• Orthostatic hypotension in hereditary transthyretin amyloidosis: epidemiology, diagnosis and management

  2019cites this paper
• Diagnosis and treatment of gastrointestinal dysfunction in hereditary TTR amyloidosis

  2019cites this paper
• Characteristics and natural history of autonomic involvement in hereditary ATTR amyloidosis: a systematic review

  2019cites this paper
• Novel RNA-targeted therapies for hereditary ATTR amyloidosis and their impact on the autonomic nervous system

  2019cites this paper
• The Clinical Autonomic Research journal 2019 and onward

  2019cites this paper
• Analysis of autonomic outcomes in APOLLO, a phase III trial of the RNAi therapeutic patisiran in patients with hereditary transthyretin-mediated amyloidosis

  2019cites this paper
• Amyloidosis: diagnosis and new therapies for a misunderstood and misdiagnosed disease.

  2019cites this paper
• Blood pressure and orthostatic hypotension as measures of autonomic dysfunction in patients from the transthyretin amyloidosis outcomes survey (THAOS).

  2019cites this paper
• Impact of Genetic Testing in Transthyretin (ATTR) Cardiac Amyloidosis

  2019cites this paper
• Characteristics of acquired transthyretin amyloidosis

  2019cites this paper
• Clinical Presentation, Diagnosis and Treatment of TTR Amyloidosis

  2019cites this paper
• Genetic neuromuscular disorders: living the era of a therapeutic revolution. Part 1: peripheral neuropathies

  2019cites this paper
• Tafamidis improves bladder function in hereditary ATTR amyloidosis

  2018cites this paper
• High-resolution axon reflex sweat testing for diagnosis of neuropathy

  2018cites this paper